Catalent, Inc. (NYSE:CTLT) Shares Acquired by XTX Topco Ltd

XTX Topco Ltd lifted its position in shares of Catalent, Inc. (NYSE:CTLT) by 191.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,348 shares of the company’s stock after acquiring an additional 15,997 shares during the quarter. XTX Topco Ltd’s holdings in Catalent were worth $1,369,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in Catalent during the fourth quarter worth approximately $116,021,000. Capital World Investors raised its stake in shares of Catalent by 6.1% during the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after buying an additional 1,098,474 shares during the period. Magnetar Financial LLC purchased a new position in shares of Catalent during the 1st quarter valued at approximately $56,429,000. Cadian Capital Management LP grew its stake in Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after acquiring an additional 759,600 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Catalent by 2,792.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock worth $29,150,000 after acquiring an additional 498,540 shares in the last quarter.

Catalent Stock Down 0.2 %

CTLT stock opened at $60.00 on Friday. The company has a current ratio of 2.52, a quick ratio of 1.77 and a debt-to-equity ratio of 1.35. The firm has a 50-day moving average of $59.48 and a two-hundred day moving average of $57.21. Catalent, Inc. has a 12 month low of $31.80 and a 12 month high of $61.20. The company has a market cap of $10.86 billion, a price-to-earnings ratio of -9.84, a PEG ratio of 1.88 and a beta of 1.15.

Analyst Ratings Changes

Several research firms have issued reports on CTLT. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. William Blair reiterated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Finally, StockNews.com initiated coverage on Catalent in a research report on Wednesday. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $58.08.

Insider Activity

In related news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares in the company, valued at $2,360,264.25. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ricky Hopson sold 662 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the transaction, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. Insiders sold 13,409 shares of company stock worth $782,923 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.